Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Status:
Active, not recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of combined treatment with
Ipilimumab and all-trans retinoic acid (ATRA) in melanoma patients.